Contrasting Entrada Therapeutics (NASDAQ:TRDA) & Alector (NASDAQ:ALEC)

Alector (NASDAQ:ALEC – Get Free Report) and Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Insider and Institutional Ownership

85.8% of Alector shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 8.3% of Alector shares are owned by company insiders. Comparatively, 9.5% of Entrada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Alector and Entrada Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alector 2 1 3 1 2.43
Entrada Therapeutics 1 2 4 0 2.43

Alector currently has a consensus target price of $5.10, suggesting a potential upside of 121.74%. Entrada Therapeutics has a consensus target price of $16.75, suggesting a potential upside of 260.99%. Given Entrada Therapeutics’ higher possible upside, analysts plainly believe Entrada Therapeutics is more favorable than Alector.

Profitability

This table compares Alector and Entrada Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Alector 23.87% 112.21% 18.37%
Entrada Therapeutics -4,057.98% -64.00% -50.49%

Valuation & Earnings

This table compares Alector and Entrada Therapeutics”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Alector $21.05 million 16.27 -$142.93 million $0.35 6.57
Entrada Therapeutics $25.42 million 7.15 -$143.75 million ($3.84) -1.21

Alector has higher earnings, but lower revenue than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Alector has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of -0.19, indicating that its stock price is 119% less volatile than the S&P 500.

Summary

Alector beats Entrada Therapeutics on 8 of the 13 factors compared between the two stocks.

About Alector

(Get Free Report)

Alector, Inc. is a biotechnology company based in South San Francisco, California, that develops investigational therapies for neurodegenerative diseases. Its research focuses on the role of the immune system in the brain and how immune pathways may be used to address disease processes. The company’s approach draws on human genetics and immunology to identify potential therapeutic targets. Its research has included programs targeting progranulin and TREM2, proteins associated with brain health and neurodegenerative disease.

About Entrada Therapeutics

(Get Free Report)

Entrada Therapeutics is a biotechnology company focused on developing medicines that deliver therapeutic molecules into cells. Founded in 2016 and based in Boston, Massachusetts, the company developed its Endosomal Escape Vehicle (EEV) platform to help move drug cargo across cellular membranes and reach intracellular targets. The company’s research centers on its EEV-based oligonucleotide medicines, including programs designed to address genetic causes of neuromuscular diseases. Its development work includes candidates intended to alter RNA processing for Duchenne muscular dystrophy, with programs targeting different genetic subgroups of the disease.

Receive News & Ratings for Alector Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alector and related companies with MarketBeat.com's FREE daily email newsletter.